Chris Whittaker

Chris Whittaker is a senior managing director in Evercore’s healthcare strategic advisory practice based in London.

Mr. Whittaker has advised on many of the most complex transactions across the pharmaceutical and biotechnology industries since joining Evercore in 2019, covering the full spectrum of M&A and strategic transaction advisory and financings, including equities and debt instruments.

Notable assignments include Novartis on the sales of its PET networks to Siemens Healthineers and its “front-of-eye” ophthalmology portfolio to Bausch + Lomb; Dimerix on its transaction with Amicus; Alliance Pharma on its acquisition by DBAY; Autolus on its collaboration with BioNTech; Product Life Group on its transaction with Oakley Capital and 21 Invest CV; SERB on its acquisition of bentracimab; Qpex Biopharma on its sale to Shionogi; Mirum on its acquisition of Travere’s bile acid portfolio and associated equity raise; and AmerisourceBergen on its acquisition of PharmaLex.

Previously, Mr. Whittaker spent 13 years at Rothschild & Co based in London.

He holds an M.A. in Natural Sciences from Christ’s College, Cambridge University, U.K., and undertook post-graduate studies at the Laboratory of Molecular & Cellular Biology at University College London.